ListarInvestigación y Desarrollo por tema "BNT162b2"
Mostrando ítems 1-1 de 1
-
Article
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom (2024)
(Taylor and Francis Ltd., 2023)Background: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. Research design & methods: We examined and compared neurological and psychiatric AEFIS ...